Skip to main content

Letter to the Editor

Impacting Global Health Delivery Through Advocacy: The Case of Losartan

Authors
  • David J. Heller
  • Sandeep P. Kishore

Abstract

Highlights

  • The WHO’s EML improves medicine access.
  • Anyone can lobby to add a medicine to the EML, so we added losartan in 2017.
  • Evidence now shows losartan is more impactful than previously realized.
  • You too can use the EML to effect policy change—by adding to or amending it.
  • Also, you can hold governments accountable to keep EML medicines on their shelves.
Published on Mar 1, 2019